Xavier Sáez-Llorens, Ximena Norero, Marisa Márcia Mussi-Pinhata, Kathia Luciani, Ignacio Salamanca de la Cueva, Javier Díez-Domingo, Eduardo Lopez-Medina, Cristina Epalza, Jerzy Brzostek, Henryk Szymański, François D Boucher, Benhur S Cetin, Tirza De Leon, Ener Cagri Dinleyici, Miguel Ángel Marín Gabriel, Tolga Ince, Mercedes Macias-Parra, Joanne M Langley, Federico Martinón-Torres, Mika Rämet, Ernest Kuchar, Jorge Pinto, Thanyawee Puthanakit, Fernando Baquero-Artigao, Guido Castelli Gattinara, Jose Manuel Merino Arribas, Jose Tomas Ramos Amador, Leszek Szenborn, Bruce Tapiero, Evan J Anderson, James D Campbell, Saul N Faust, Vanja Nikic, Yingjun Zhou, Wenji Pu, Damien Friel, Ilse Dieussaert, Antonio Gonzalez Lopez, Roderick McPhee, Sonia K Stoszek, Nicolas Vanhoutte
BACKGROUND: Respiratory syncytial virus (RSV) is a common cause of lower respiratory tract infections in infants. This phase 1/2, observer-blind, randomized, controlled study (ClinicalTrials.gov/NCT03636906) assessed the safety and immunogenicity of an investigational chimpanzee-derived adenoviral vector RSV vaccine (ChAd155-RSV, expressing RSV F, N, and M2-1) in infants. METHODS: Healthy 6-7-month-olds were 1:1:1-randomized to receive: 1 low ChAd155-RSV dose (1...
July 21, 2023: Journal of Infectious Diseases